Payment overview · 2025
General Payments
$688.76
30 reported records · 12 companies
Healthcare provider profile · identity verified
Ajaz Umerani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, OH · NPI 1104927797
Verified facts
What the public records show
CMS Open Payments records show Ajaz Umerani, M.D. received $688.76 in general payments during 2025 across 30 reported records.
Organogenesis Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $158.79 | 23.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.53 | 15.0% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$98.38 | 14.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.48 | 11.0% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $74.30 | 10.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.99 | 5.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.14 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.69 | 4.5% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $29.02 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.69 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.65 | 2.4% | 1 | 2025 |
| BLUEWIND MEDICAL | Unresolved — no canonical attribution shown | $16.10 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $688.76 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $115.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.48 | 4 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $74.30 | 3 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $66.72 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.57 | 3 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $43.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.69 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.69 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CLOSURERFS Normalized: closurerfs |
Device | Medtronic, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| REVI Normalized: revi |
Device | BLUEWIND MEDICAL | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 79 |
| Omeprazole | Omeprazole | 229 | 79 |
| Losartan Potassium | Losartan Potassium | 205 | 63 |
| Metformin Hcl | Metformin Hcl | 189 | 65 |
| Lisinopril | Lisinopril | 183 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 68 |
| Furosemide | Furosemide | 151 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 48 |
| Simvastatin | Simvastatin | 139 | 46 |
| Glimepiride | Glimepiride | 135 | 45 |
| Eliquis | Apixaban | 126 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 43 |
| Potassium Chloride | Potassium Chloride | 118 | 33 |
| Gabapentin | Gabapentin | 117 | 40 |
| Carvedilol | Carvedilol | 115 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 29 |
| Methylprednisolone | Methylprednisolone | 95 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Sertraline Hcl | Sertraline Hcl | 81 | 22 |
| Farxiga | Dapagliflozin Propanediol | 80 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 25 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Famotidine | Famotidine | 66 | 25 |
| Trazodone Hcl | Trazodone Hcl | 66 | 21 |
| Alendronate Sodium | Alendronate Sodium | 65 | 21 |
| Allopurinol | Allopurinol | 65 | 21 |
| Torsemide | Torsemide | 64 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 28 |
| Spironolactone | Spironolactone | 60 | 24 |
| Synthroid | Levothyroxine Sodium | 60 | 20 |
| Ozempic | Semaglutide | 59 | 13 |
| Valsartan | Valsartan | 59 | 17 |
| Mirtazapine | Mirtazapine | 55 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 20 |
| Donepezil Hcl | Donepezil Hcl | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | 15 |
| Gemfibrozil | Gemfibrozil | 49 | 13 |
| Azithromycin | Azithromycin | 47 | 42 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Memantine Hcl | Memantine Hcl | 47 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 16 |
| Midodrine Hcl | Midodrine Hcl | 45 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 44 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 23 |
| Alprazolam | Alprazolam | 42 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Finasteride | Finasteride | 41 | suppressed |
| Prednisone | Prednisone | 41 | 22 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | 14 |
| Risedronate Sodium | Risedronate Sodium | 40 | suppressed |
| Atenolol | Atenolol | 39 | 13 |
| Celecoxib | Celecoxib | 38 | 14 |
| Clonidine Hcl | Clonidine Hcl | 38 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Ramipril | Ramipril | 35 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 11 |
| Klor-Con M20 | Potassium Chloride | 31 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 12 |
| Meloxicam | Meloxicam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Etodolac | Etodolac | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | 11 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $688.76 · 30 records | Organogenesis Inc. | AFFINITY, BREZTRI, CAMZYOS, CLOSUREFAST, CLOSURERFS, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Flexitouch Plus, LINZESS, MOUNJARO, NURTEC ODT, Nimbl, PROLIA, PURAPLY WOUND MATRIX, REVI, VENASEAL, Varithena Administration Pack, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error